Johnson & Johnson has applied to the European Medicines Agency for approval of a subcutaneous version of RYBREVANT® (amivantamab) to treat patients with EGFR-mutated non-small cell lung cancer.

Strand Therapeutics has declared that the initial patient has received a dosage in their Phase 1, first-in-human study of STX-001.

Bristol Myers Squibb has revealed that the U.S. Food and Drug Administration has given the green light to Breyanzi® (lisocabtagene maraleucel; liso-cel).

On June 3, the official website of Structure Therapeutics announced top-line data from its 12-week clinical Phase 2a study of the investigational drug GSBR-1290 in obesity.

Jun 5th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

On May 22, Biogen Inc. and Human Immunology Biosciences (HI-Bio) announced an acquisition agreement. Biogen will acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.

Jun 4th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The European Commission has approved Bristol Myers Squibb's Opdivo® (nivolumab) combined with cisplatin and gemcitabine for first-line therapy in adults with unresectable or metastatic urothelial carcinoma.

5.27-6.2 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Jazz Pharmaceuticals plc revealed that the U.S. Food and Drug Administration (FDA) has accepted and given Priority Review status to the Biologics License Application (BLA) for zanidatamab.

Full-Life Technologies Receives FDA IND Clearance for 225Ac-FL-020 to Treat Metastatic Castration-Resistant Prostate Cancer.

VBI Vaccines Releases New Tumor Response Results from Ongoing Phase 2b Study of VBI-1901 in Patients with Recurrent Glioblastoma.